Home/Pipeline/RELVAR/BREO ELLIPTA

RELVAR/BREO ELLIPTA

Asthma, COPD

CommercialRoyalty Revenue Generating

Key Facts

Indication

Asthma, COPD

Phase

Commercial

Status

Royalty Revenue Generating

Company

Innoviva

About Innoviva

Innoviva operates a distinctive hybrid business model, leveraging long-term royalty streams from partnered respiratory drugs like TRELEGY and ANORO to fund strategic R&D and acquisitions. The company has successfully transitioned from its origins as Theravance into a financially robust entity with a $1.69B market cap, using its cash generation to build a promising pipeline in oncology and anti-infectives. Its strategy focuses on disciplined capital allocation, targeting late-stage or commercial assets to drive future growth while maintaining a strong balance sheet.

View full company profile

Therapeutic Areas

Respiratory Infectious Disease Oncology

Other Asthma, COPD Drugs

Drug	Company	Phase	Status
HBM9378 (SKB378/WIN378)	Harbour BioMed	Phase 1	Active (Greater China)
HP-Betadex DPI Formulations	Aquilon Pharmaceuticals	Clinical	Active
Generic Advair (Fluticasone/Salmeterol)	Lupin Limited	ANDA Filed/Approved	Active
Respiratory Inhalation Portfolio (Generic)	Cipla	ANDA Filed/Approved	Active
Wixela Inhub (Fluticasone/Salmeterol)	Viatris	Launched	Marketed (US, Authorized Generic)
QX008N	Qyuns Therapeutics	Phase 1	Active